Log in to save to my catalogue

Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice

Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2671036

Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice

About this item

Full title

Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice

Publisher

Alexandria, VA: American Diabetes Association

Journal title

Diabetes (New York, N.Y.), 2009-05, Vol.58 (5), p.1144-1155

Language

English

Formats

Publication information

Publisher

Alexandria, VA: American Diabetes Association

More information

Scope and Contents

Contents

Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice
Andrew P.R. Sutherland 1 , 2 ,
Tom Van Belle 3 ,
Andrea L. Wurster 1 ,
Akira Suto 1 ,
Monia Michaud 1 ,
Dorothy Zhang 1 ,
Michael J. Grusby 1 , 4 and
Matthias von Herrath 3
1 Department of Immunology and Infectious Diseases, Harvard School of Public Health, Boston, Massachusetts;
2 John Curtin School of Medical Research, Australian National University, Canberra, Australia;
3 Department of Developmental Immunology, La Jolla Institute for Allergy and Immunology, La Jolla, California;
4 Division of Rheumatology, Immunology and Allergy, Brigham and Women's Hospital and Department of Medicine, Harvard Medical
School, Boston, Massachusetts.
Corresponding author: Matthias von Herrath, matthias{at}liai.org , and Michael Grusby, mgrusby{at}hsph.harvard.edu .
A.P.R.S. and T.V.B. contributed equally to this work.
Abstract
OBJECTIVE Interleukin (IL)-21 is a type 1 cytokine that has been implicated in the pathogenesis of type 1 diabetes via the unique biology
of the nonobese diabetic (NOD) mouse strain. The aim of this study was to investigate a causal role for IL-21 in type 1 diabetes.
RESEARCH DESIGN AND METHODS We generated IL-21R–deficient NOD mice and C57Bl/6 mice expressing IL-21 in pancreatic β-cells, allowing the determination
of the role of insufficient and excessive IL-21 signaling in type 1 diabetes.
RESULTS Deficiency in IL-21R expression renders NOD mice resistant to insulitis, production of insulin autoantibodies, and onset
of type 1 diabetes. The lymphoid compartment in IL-21R −/− NOD is normal and does not contain an increased regulatory T-cell fraction or diminished effector cytokine responses. However,
we observed a clear defect in autoreactive effector T-cells in IL-21R −/− NOD by transfer experiments. Conversely, overexpression of IL-21 in pancreatic β-cells induced inflammatory cytokine and
chemokines, including IL-17A, IL17F, IFN-γ, monocyte chemoattractant protein (MCP)-1, MCP-2, and interferon-inducible protein-10
in the pancreas. The ensuing leukocytic infiltration in the islets resulted in destruction of β-cells and spontaneous type
1 diabetes in the normally diabetes-resistant C57Bl/6 and NOD × C57Bl/6 backgrounds.
CONCLUSIONS This work provides demonstration of the essential prodiabetogenic activities of IL-21 on diverse genetic backgrounds (NOD
and C57BL/6) and indicates that IL-21 blockade could be a promising strategy for interventions in human type 1 diabetes.
Footnotes
The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore
be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.
Received August 13, 2008.
Accepted January 31, 2009.
Readers may use this article as long as the work is properly cited, the use is educational and not for profit, and the work
is not altered. See http://creativecommons.org/licenses/by-nc-nd/3.0/ for details.
© 2009 by the American Diabetes Association....

Alternative Titles

Full title

Interleukin-21 Is Required for the Development of Type 1 Diabetes in NOD Mice

Identifiers

Primary Identifiers

Record Identifier

TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2671036

Permalink

https://devfeature-collection.sl.nsw.gov.au/record/TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_2671036

Other Identifiers

ISSN

0012-1797

E-ISSN

1939-327X

DOI

10.2337/db08-0882

How to access this item